TScan Therapeutics, Inc. (NASDAQ:TCRX – Get Rating) was the target of a large growth in short interest in the month of May. As of May 15th, there was short interest totalling 417,400 shares, a growth of 365.8% from the April 30th total of 89,600 shares. Currently, 2.9% of the company’s shares are sold short. Based on an average daily volume of 1,280,000 shares, the days-to-cover ratio is currently 0.3 days.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of TScan Therapeutics in a report on Thursday, March 9th.
Institutional Trading of TScan Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of TCRX. BlackRock Inc. lifted its stake in shares of TScan Therapeutics by 1.4% during the first quarter. BlackRock Inc. now owns 1,519,188 shares of the company’s stock valued at $4,254,000 after acquiring an additional 20,650 shares during the period. Alphabet Inc. acquired a new position in shares of TScan Therapeutics during the third quarter valued at $3,285,000. Simplify Asset Management Inc. bought a new stake in shares of TScan Therapeutics in the first quarter worth about $1,149,000. Vanguard Group Inc. increased its holdings in shares of TScan Therapeutics by 13.9% in the third quarter. Vanguard Group Inc. now owns 257,416 shares of the company’s stock worth $785,000 after acquiring an additional 31,352 shares in the last quarter. Finally, Woodline Partners LP increased its holdings in shares of TScan Therapeutics by 37.1% in the first quarter. Woodline Partners LP now owns 136,930 shares of the company’s stock worth $383,000 after acquiring an additional 37,030 shares in the last quarter. 48.21% of the stock is currently owned by institutional investors.
TScan Therapeutics Stock Performance
TScan Therapeutics (NASDAQ:TCRX – Get Rating) last issued its quarterly earnings results on Wednesday, March 8th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.05). The business had revenue of $3.10 million during the quarter, compared to the consensus estimate of $2.63 million. TScan Therapeutics had a negative return on equity of 68.23% and a negative net margin of 419.38%. Equities research analysts forecast that TScan Therapeutics will post -2.84 earnings per share for the current fiscal year.
About TScan Therapeutics
TScan Therapeutics, Inc, a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors.
- Get a free copy of the StockNews.com research report on TScan Therapeutics (TCRX)
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
Receive News & Ratings for TScan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TScan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.